The Sai Parenterals Limited IPO has entered the primary market, attracting attention from investors looking to tap into the growing pharmaceutical sector in India. With a strong presence in branded generics and CDMO services, the company is positioning itself as a key player in both domestic and international markets.

The IPO, which opened on March 24, 2026, and closes on March 27, 2026, is a book-built issue worth ₹408.79 crore, combining both fresh issue and offer for sale components. As the pharmaceutical sector continues to expand, this IPO presents an opportunity for investors to participate in a diversified and research-driven pharma business.

About Sai Parenterals Limited

Sai Parenterals Limited operates in the pharmaceutical formulations industry, focusing on the research, development, and manufacturing of medicines.

The company has built a strong foundation through two key verticals:

1. Branded Generic Formulations
2. Contract Development and Manufacturing Organisation CDMO services

This dual business model allows the company to generate revenue from both product sales and service-based contracts, ensuring diversification and stability.

Product Portfolio and Therapeutic Areas

Sai Parenterals has a wide and diversified product portfolio, covering multiple therapeutic segments such as:

• Cardiovascular diseases
• Neuropsychiatry
• Anti-diabetic treatments
• Respiratory medicines
• Antibiotics
• Gastroenterology
• Vitamins and supplements
• Analgesics and dermatology products

The company manufactures medicines in various dosage forms including:

• Injectables
• Tablets and capsules
• Liquid orals
• Ointments

This diversity helps the company cater to a broad customer base and multiple healthcare needs.

Revenue Model Explained

Sai Parenterals earns revenue through:

• Sale of branded generic medicines to hospitals, government agencies, distributors and pharma companies
• CDMO services, which include product development, regulatory support and commercial manufacturing for global clients

The CDMO segment is particularly important as it offers long-term contracts, stable revenue streams and global exposure.

Sai Parenterals IPO Details

The IPO comes with the following key details:

• Issue Size: ₹408.79 crore
• Fresh Issue: ₹285.00 crore
• Offer for Sale: ₹123.79 crore
• Price Band: ₹372 to ₹392 per share
• Lot Size: 38 shares
• Minimum Investment for Retail: ₹14,896
• Minimum Investment for HNI: ₹2,08,544

IPO Timeline

• IPO Open Date: March 24, 2026
• IPO Close Date: March 27, 2026
• Allotment Date: Expected on March 30, 2026
• Listing Date: Expected on April 02, 2026
• Listing Exchange: NSE and BSE

These timelines are important for investors planning to apply and track allotment and listing gains.

Market Capitalisation and Valuation

At the upper price band of ₹392 per share, the company’s market capitalisation is estimated at around ₹1,731.83 crore.

This valuation reflects:

• Growth potential in pharma sector
• Expansion of CDMO services
• Diversified product portfolio

However, investors must carefully evaluate whether the valuation is justified based on financial performance and future growth prospects.

Role of Lead Managers and Registrar

• Book Running Lead Manager: Arihant Capital Markets Limited
• Registrar: Bigshare Services Private Limited

These entities are responsible for managing the IPO process and ensuring smooth allotment and listing.

Grey Market Premium Insight

The Grey Market Premium of Sai Parenterals IPO is currently around ₹0, indicating:

• Neutral investor sentiment
• No strong indication of listing gains
• Balanced demand and supply in the unofficial market

It is important to note that GMP is not a reliable indicator and should only be used for informational purposes.

Strengths of the Company

Sai Parenterals has several strengths that make it an interesting IPO:

1. Diversified Business Model
   Combination of branded generics and CDMO services reduces dependency on a single revenue stream.
2. Wide Therapeutic Coverage
   Presence across multiple medical segments ensures consistent demand.
3. Global CDMO Opportunities
   CDMO services provide access to international markets and long-term contracts.
4. Established Industry Presence
   The company has built relationships with hospitals, government agencies and pharma companies.

Risks to Consider

Despite its strengths, investors should also consider potential risks:

1. Highly Competitive Industry
   Pharmaceutical sector is crowded with established players.
2. Regulatory Risks
   Strict regulations in domestic and international markets can impact operations.
3. Pricing Pressure
   Government policies and competition can affect profit margins.
4. GMP Neutral Trend
   Lack of strong grey market premium may indicate limited short-term listing gains.

Investment Perspective

The Sai Parenterals IPO can be viewed from two perspectives:

Short-Term View

• GMP is neutral, so listing gains may be limited
• Market conditions and subscription demand will play a key role

Long-Term View

• Strong growth potential in pharma sector
• CDMO business can drive future expansion
• Diversified portfolio supports stability

Investors with a long-term horizon may find this IPO more attractive compared to short-term traders.

Pharma Sector Outlook

The Indian pharmaceutical sector is expected to grow due to:

• Rising healthcare demand
• Increasing exports
• Government support for manufacturing
• Growth in contract manufacturing services

Companies with CDMO capabilities are particularly well-positioned to benefit from global outsourcing trends.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.